T1	Participants 178 434	Twenty-eight newly diagnosed patients with small cell lung cancer were randomized to receive either high-dose or standard-dose cyclophosphamide, vincristine, and semustine in a trial where the dose of induction chemotherapy was the sole treatment variable.
T2	Participants 476 582	57% of patients receiving high-dose therapy as compared to 21% of patients receiving standard-dose therapy
T3	Participants 819 850	the median survival in patients
T4	Participants 992 1023	patients with extensive disease
T5	Participants 1180 1223	A small group of patients appear to benefit
